Post
of 161,621
You are pulling on the right strings here, but the AI you asked gave you a standard textbook answer which misses the clinical physics of what CytoDyn is actually setting up.
It is true that ctDNA (circulating tumor DNA) is heavily used to monitor ICI success, but ctDNA is not exclusive to ICIs.
Think of ctDNA as the "body count." When tumor cells die, they burst and shed their DNA into the bloodstream. By measuring this, clinicians get a real-time picture of whether a tumor is growing or shrinking. You can use ctDNA to measure the success of any therapy that attacks cancer, like chemotherapy and radiation.
So, why is Hoffman pairing "Initial PD-L1/ctDNA readouts" for Q1 2026?
Because CytoDyn isn't trying to prove they have the best ICI on the market. They are proving that Leronlimab is the Universal Primer for somebody else's ICI (like Merck's Keytruda or Roche's Tecentriq).
They are preparing to hand Big Pharma a safe, flawless, undeniable two-part package:
The Unmasking (PD-L1 Readout): This proves the M1/M2 macrophage Inversion works. It proves Leronlimab successfully turns a "Cold" Tumor "Hot," stripping away its defenses so the Immune System can see it.
The Body Count (ctDNA Readout): This proves that once the tumor is unmasked, it is actually taking on damage and shrinking in real-time.
To answer your specific thought, do they need to be running an active ICI combo trial right now to make this work? No. If CytoDyn can show massive PD-L1 upregulation combined with ctDNA clearance using Leronlimab (even just alongside standard of care), they have handed Big Pharma the Holy Grail. Merck does not need CytoDyn to fund a massive Phase 3 ICI combo trial; Merck has billions of dollars to do that themselves, if they even need to given the new FDA Framework.
What Big Pharma needs right now is the de-risked, early-stage biological proof that Leronlimab physically alters the tumor microenvironment. That Q1 2026 readout is the definitive "Sign" required to justify a corporate Bolt-On Acquisition or a massive partnership. They are setting the table for the buyout.
It is true that ctDNA (circulating tumor DNA) is heavily used to monitor ICI success, but ctDNA is not exclusive to ICIs.
Think of ctDNA as the "body count." When tumor cells die, they burst and shed their DNA into the bloodstream. By measuring this, clinicians get a real-time picture of whether a tumor is growing or shrinking. You can use ctDNA to measure the success of any therapy that attacks cancer, like chemotherapy and radiation.
So, why is Hoffman pairing "Initial PD-L1/ctDNA readouts" for Q1 2026?
Because CytoDyn isn't trying to prove they have the best ICI on the market. They are proving that Leronlimab is the Universal Primer for somebody else's ICI (like Merck's Keytruda or Roche's Tecentriq).
They are preparing to hand Big Pharma a safe, flawless, undeniable two-part package:
The Unmasking (PD-L1 Readout): This proves the M1/M2 macrophage Inversion works. It proves Leronlimab successfully turns a "Cold" Tumor "Hot," stripping away its defenses so the Immune System can see it.
The Body Count (ctDNA Readout): This proves that once the tumor is unmasked, it is actually taking on damage and shrinking in real-time.
To answer your specific thought, do they need to be running an active ICI combo trial right now to make this work? No. If CytoDyn can show massive PD-L1 upregulation combined with ctDNA clearance using Leronlimab (even just alongside standard of care), they have handed Big Pharma the Holy Grail. Merck does not need CytoDyn to fund a massive Phase 3 ICI combo trial; Merck has billions of dollars to do that themselves, if they even need to given the new FDA Framework.
What Big Pharma needs right now is the de-risked, early-stage biological proof that Leronlimab physically alters the tumor microenvironment. That Q1 2026 readout is the definitive "Sign" required to justify a corporate Bolt-On Acquisition or a massive partnership. They are setting the table for the buyout.
23